Retatrutide + Cagrilintide
Single vial containing 5mg Retatrutide + 5mg Cagrilintide — triple agonist (GLP-1/GIP/glucagon) paired with amylin receptor agonist for combined metabolic, satiety, and weight-regulation research
Select size
For research purposes only. Not for human consumption.
Mechanism of Action
A dual-peptide research blend pairing Retatrutide (a triple GLP-1 / GIP / glucagon receptor agonist) with Cagrilintide (a long-acting amylin and calcitonin receptor agonist). The combination targets complementary incretin, glucagon, and amylin pathways to investigate synergistic effects on satiety, energy expenditure, gastric emptying, and adipose tissue remodeling in metabolic research models.
How It Works
- 1
Retatrutide co-activates GLP-1, GIP, and glucagon receptors — driving insulin secretion, delayed gastric emptying, and increased basal energy expenditure
- 2
Cagrilintide binds amylin (AMY1–3) and calcitonin receptors in the hindbrain to prolong satiety signaling and reduce meal size
- 3
Glucagon-arm activation from Retatrutide promotes hepatic lipolysis and thermogenesis, complementing amylin-driven appetite suppression
- 4
Amylin co-agonism slows postprandial glucose excursions and modulates food-reward pathways independent of the GLP-1 axis
- 5
Combined action targets multiple, non-overlapping nodes of energy balance — a leading strategy in next-generation obesity and metabolic disease research (cf. CagriSema, MariTide programs)
Key Research Benefits
- Multi-receptor metabolic research (GLP-1 / GIP / glucagon / amylin)
- Satiety, appetite regulation, and food-reward pathway studies
- Adipose tissue remodeling and thermogenesis models
- Glycemic control and insulin sensitivity investigation
- Comparative research vs Retatrutide or Cagrilintide monotherapy
- Next-generation combination-agonist protocol development
The Retatrutide + Cagrilintide pairing follows the same combination-agonist thesis validated by Novo Nordisk's CagriSema (Cagrilintide + Semaglutide) and Amgen's MariTide programs — leveraging complementary incretin and amylin signaling for magnified metabolic effects at lower individual doses. Each 10mg vial contains 5mg Retatrutide + 5mg Cagrilintide. Strictly research use only — not for human or veterinary administration.